Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Acrivon Therapeutics Inc (ACRV)

42 + Investors. Track Smart Money conviction in ACRV. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -6
Streak
1Q ▼
Buyers last Q
45%

Smart Money Signals — ACRV

Based on 42 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their ACRV positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 70% of 3.0Y peak

70% of all-time peak
42 funds currently hold this stock — 70% of the 3.0-year high of 60 funds (reached 2025 Q1). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📉

Outflows — 30% fewer funds vs a year ago

fund count last 6Q
18 fewer hedge funds hold ACRV compared to a year ago (-30% decline). When institutions consistently reduce their exposure, it's worth exploring the underlying fundamental reasons driving them away.
🟠

More sellers than buyers — 45% buying

20 buying24 selling
Last quarter: 24 funds reduced or exited vs 20 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
➡️

Steady new buyers — ~9 new funds per quarter

new funds entering per quarter
Funds opening this position for the first time: 16 → 6 → 8 → 9. A stable flow of new institutional buyers suggests ongoing interest without signs of either acceleration or slowdown.
🔒

48% of holders stayed for 2+ years

■ 48% conviction (2yr+) ■ 31% medium ■ 21% new
20 out of 42 hedge funds have held ACRV for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares -11%, value -51%

Value
-51%
Shares
-11%
Last quarter: funds added -11% more shares while total portfolio value only changed -51%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
📊

Peak discovery — momentum slowing

8 → 16 → 6 → 8 → 9 new funds/Q
New funds entering each quarter: 16 → 6 → 8 → 9. ACRV is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 50% veterans vs 24% newcomers

■ 50% veterans ■ 26% 1-2yr ■ 24% new
Entry-cohort mix of 42 holders: 21 (50%) are 2+ year veterans, 11 entered 1–2 years ago, and 10 (24%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 10% AUM from top-100

10% from top-100 AUM funds
14 of 42 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
2.3
out of 10
Low Exit Risk
Exit risk score 2.3/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — ACRV

In 2026 Q1, 20 hedge funds were net buyers of ACRV (9 opened a new position, 11 added to an existing one), while 24 reduced or exited (9 trimmed, 15 sold completely) — a 45% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: -6 funds (more exits than new entries). Total institutional holders: 42.

Hedge Fund Ownership: ACRV

How many hedge funds hold ACRV — quarterly history vs. share price
Quarterly hedge fund ownership of ACRV vs. share price

Market Analysis: ACRV

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: ACRV

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Acrivon Therapeutics Inc (ACRV) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much ACRV has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 83d ago
ACRV
+16.5%
XLV
+708.6%

ACRV outperformed XLV by -692.1% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 38d ago
ACRV
-8.5%
XLV
+695.5%

Since the filing became public, ACRV outperformed XLV by -704.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 0 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: ACRV
42 + Investors

Track Smart Money conviction in ACRV. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 42 48 -12.5%
13F Shares 17M 19M -11.03%
Total Value $22M $45M -50.99%
New Positions 9 8 +1
Increased Positions 11 16 -5
Closed Positions 15 6 +9
Reduced Positions 9 10 -1
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: ACRV

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

42 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in ACRV. Verified SEC 13F-HR filings.

QUARTER:
Top 25 ACRV holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Sands Capital Alternatives, LLC 0.70% 2,122,605 $3.0M
2 Ra Capital Management, L.P. 0.12% 8,340,508 $11.6M
3 AAF Wealth Management, LLC 0.01% 10,678 $15K
4 Bridgeway Capital Management, LLC 0.00% 158,900 $221K
5 Prelude Capital Management, LLC 0.00% 24,015 $33K
6 Two Sigma Securities, LLC 0.00% 11,679 $16K
7 Renaissance Technologies LLC 0.00% 758,440 $1.1M
8 XTX Topco Ltd 0.00% 66,882 $93K
9 Two Sigma Advisers, LP 0.00% 333,773 $804K
10 Marshall Wace, LLP 0.00% 560,436 $779K
11 Redwood Park Advisors LLC 0.00% 500 —
12 Two Sigma Investments, LP 0.00% 389,395 $541K
13 Wellington Management Group LLP 0.00% 888,130 $1.2M
14 Panagora Asset Management Inc 0.00% 33,814 $47K
15 Tower Research Capital LLC (TRC) 0.00% 4,526 $6K
16 Squarepoint Ops LLC 0.00% 27,472 $38K
17 Jane Street Group, LLC 0.00% 239,691 $333K
18 Vanguard Fiduciary Trust Co 0.00% 107,529 $149K
19 Vanguard Capital Management LLC 0.00% 722,035 $1.0M
20 Federated Hermes, INC. 0.00% 7,924 $11K
21 UBS Group AG 0.00% 34,634 $48K
22 BlackRock, Inc. 0.00% 208,939 $290K
23 Morgan Stanley 0.00% 36,671 $51K
24 Nisa Investment Advisors, LLC 0.00% 584 —
25 SBI Securities Co., Ltd. 0.00% 74 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Acrivon Therapeutics Inc (ACRV)

What does the Smart Money Trend signal show for ACRV?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their ACRV positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for ACRV?

More sellers than buyers — 45% buying: Last quarter: 24 funds reduced or exited vs 20 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for ACRV holders?

Smaller funds dominant — 10% AUM from top-100: 14 of 42 holders rank in the top 100 by AUM, but together hold only 10% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held ACRV?

48% of holders stayed for 2+ years: 20 out of 42 hedge funds have held ACRV for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Acrivon Therapeutics Inc (ACRV) following the 2026 Q1 hedge fund 13F filings?

As of today, ACRV has moved -8.5% since the 2026 Q1 13F filing date (May 15, 2026), compared to +695.5% for the XLV sector ETF — an outperformance of -704.0%. Since the quarter end (March 31, 2026), ACRV has gained +16.5% vs +708.6% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →